Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Author's Avatar
Mar 30, 2023

Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors